Avenue Therapeutics, Inc.
ATXI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | -0.00 |
| FCF Yield | 15.29% | -27.55% | -133.06% | -23.88% |
| EV / EBITDA | 1.66 | -9.05 | 1.37 | -0.34 |
| Quality | ||||
| ROIC | -31.66% | 10.49% | -81.69% | -85.99% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.55 | -0.53 | 0.64 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,119,653.35% | 1,119,653.35% | -100.00% | -100.00% |
| Free Cash Flow Growth | 317.61% | 85.16% | -55.24% | 73.55% |
| Safety | ||||
| Net Debt / EBITDA | 5.12 | -11.20 | 1.84 | 1.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 51.28 | 0.00 | 0.00 |